Results 11 to 20 of about 291 (113)
Frontiers in Endocrinology, 2022 Adult growth hormone deficiency (AGHD) is a rare endocrine disorder characterized by an abnormal body composition, metabolic abnormalities associated with increased cardiovascular diseases, bone loss, and impaired quality of life.
Martin Bidlingmaier +6 more
doaj +6 more sources
Somapacitan-induced reversible lipoatrophy in an adult woman with hypopituitarism. [PDF]
PituitaryAbstract Background Lipoatrophy is rare adverse event (AE) in daily recombinant human growth hormone (rhGH). Data on lipoatrophy in newly developed long-acting GH (LAGH) are scarce. We report the first case of lipoatrophy in adult patient treated with LAGH somapacitan. Case presentation
Rakusa M, Janez A, Jensterle M.
europepmc +4 more sources
Tissue Distribution and Receptor Activation by Somapacitan, a Long Acting Growth Hormone Derivative [PDF]
International Journal of Molecular Sciences, 2020 Somapacitan is a long-acting, once-weekly, albumin-binding growth hormone (GH) derivative. The reversible albumin-binding properties leads to prolonged circulation half-life. Here, we investigated and compared somapacitan with human GH on downstream receptor signaling in primary hepatocytes and hepatocellular models and using isothermal titration ...
Tomáš Alanentalo +2 more
exaly +4 more sources
Journal of Clinical Endocrinology and Metabolism, 2023 Abstract Context Growth hormone deficiency (GHD) in children is currently treated with daily injections of GH, which can be burdensome for patients and their parents/guardians. Somapacitan is a GH derivative in development for once-weekly treatment of GHD.
Tadej Battelino, Meryl Brod
exaly +3 more sources
Pituitary, 2022 Abstract Purpose The long-term effects of long-acting growth hormone (LAGH) analogues on glucose metabolism in adult growth hormone deficiency (AGHD) are not known. We investigated the impact of LAGH somapacitan, administered once-weekly, on glucose metabolism in patients with AGHD. Methods
Hidenori Fukuoka, Navid Nedjatian
exaly +3 more sources
Once-weekly Somapacitan is Effective and Well Tolerated in Adults with GH Deficiency: A Randomized Phase 3 Trial [PDF]
Journal of Clinical Endocrinology and Metabolism, 2020 Abstract Context Growth hormone (GH) replacement requires daily GH injections, which is burdensome for some adult patients with GH deficiency (AGHD). Objective To demonstrate efficacy and safety of somapacitan, a once-weekly ...
, , Gudmundur Johannsson
exaly +4 more sources
Once-Weekly Somapacitan vs Daily GH in Children With GH Deficiency: Results From a Randomized Phase 2 Trial [PDF]
Journal of Clinical Endocrinology and Metabolism, 2020 Abstract Context Daily growth hormone (GH) injections can be burdensome for patients and carers. Somapacitan is a long-acting, reversible albumin-binding GH derivative in development for once-weekly administration in patients with growth hormone deficiency (GHD).
Kei Takasawa +2 more
exaly +3 more sources
Journal of Clinical Endocrinology and Metabolism, 2022 Abstract Context Somapacitan, a once-weekly reversible albumin-binding GH derivative, is evaluated in children with GH deficiency (GHD). Objective To demonstrate efficacy and safety of somapacitan vs daily GH.
Jun Mori, , Michel Polak
exaly +3 more sources
Journal of the Endocrine Society, 2023 Abstract Context Growth hormone (GH) replacement therapy improves longitudinal growth and adult height in children with GH deficiency (GHD). GH stimulates insulin-like growth factor (IGF)-I release, the biomarker used for monitoring GH activity during treatment.
Rasmus Juul Kildemoes, Jun Mori
exaly +3 more sources
Clinical Endocrinology, Volume 100, Issue 4, Page 389-398, April 2024.Abstract Objective Somapacitan is a long‐acting growth hormone (GH) derivative developed for the treatment of GH deficiency (GHD). This study evaluates the efficacy and tolerability of somapacitan in Japanese children with GHD after 104 weeks of treatment and after switch from daily GH.
Jun Mori +7 more
wiley +3 more sources